Physician profile
Robert Zaiden
NPI 1821143710
$3,555.68
in general payments reported to CMS, 2019-2025
18 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $12.90 · 2021: $39.52 · 2022: $1,066 · 2023: $221 · 2024: $365 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,263 · Food and Beverage: $922 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,262.50 |
| Food and Beverage | $922.06 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,262.50 | 2025 | Erleada |
| Aveo Pharmaceuticals, INC. | $1,050.00 | 2022 | |
| Exelixis INC. | $350.58 | 2021-2025 | Cabometyx |
| Intera Oncology, INC | $253.40 | 2024-2025 | Intera |
| Caris Mpi, INC. | $150.13 | 2025 | Mi Cancer Seek |
| Boston Scientific Corporation | $146.20 | 2023 | |
| Comsort, INC | $100.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $48.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.90 | 2019 | |
| Rigel Pharmaceuticals, INC. | $28.45 | 2023 | Tavalisse, Rezlidhia |
| Gilead Sciences, INC. | $23.26 | 2019 | |
| Celgene Corporation | $16.71 | 2025 | Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $12.90 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zaiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.